Prolyl hydroxylase EGLN2

BE0002211ProteinHumansEGLN2

Prolyl hydroxylase that mediates hydroxylation of proline residues in target proteins, such as ATF4, IKBKB, CEP192 and HIF1A (PubMed:11595184, PubMed:12039559, PubMed:15925519, PubMed:16509823, PubMed:17114296, PubMed:23932902). It is acted on by 8 drugs in DrugBank.

Gene name
EGLN2
UniProtKB entry
Q96KS0Swiss-Prot
Cellular location
Nucleus
Residues / weight
407 residues · 43,650 Da
Also known as
1.14.11.- · Egl nine homolog 2 · EIT-6 · EIT6 · Estrogen-induced tag 6

Resolves to

Protein
UniProtQ96KS0UniProt nameEGLN2_HUMAN
Gene
HGNCHGNC:14660NCBI Gene112398GenBank14547148GeneCardsEGLN2
Pharmacology
IUPHAR/GtoPdb2832KEGGhsa:112398
Structure
PDB5V1B
Drugs

What you can answer from here — as of September 03, 2024

8DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
13GO termsFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
45+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Prolyl hydroxylase EGLN2, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In